Hybridoma Development and Monoclonal Antibody Generation · Hybridoma Development and Monoclonal...
2
Hybridoma Development and Monoclonal Antibody Generation ChemPartner provides premium monoclonal antibody services based on our advanced hybridoma platform which is validated by over 30 therapeutic projects and a large number of reagent mAb projects. A number of key technologies including biofunctional protein production, over-expressing stable cell line generation, tolerance breaking technologies, success guaranteed hybridoma generation, high throughput cell based screening and media compatible bioassay development and protein analytics are integrated into this platform to ensure the success of mAb development for therapeutic candidates and broad range of assay applications. To date, we have worked with over 50 biotech and pharmaceutical companies and research institutes worldwide and delivered antibodies meeting the desired specifications and successfully in their assays and product development. We are continuously improving our service platforms and expanding our capabilities in the demanding areas such as GPCR/ion-channel antibody and ADC antibody discovery. 998 Halei Road #5 Zhangjiang Hi-Tech Park PudongShanghai, China 201203 China: +86 21 5132 0000 USA: +1 781 996 5291 Europe: +45 4586 9000 Japan: +81 3 62027441 [email protected] www.chempartner.com Recombinant protein production Stable cell line generation Peptide/compound synthesis and protein conjugation Plasmid DNA construction and bullet preparation Low-medium throughput High throughput Low throughput Flow cytometry (FACS) Acumen microplate cytometry Immunocytochemistry (ICC/IHC) SPF grade and multiple species/strain CPSJ mice with superior immune response Transgenic mice for fully human antibody generation Genetic immunization Proliferation assay Apoptosis assay Migration assay Soft agar colony formation assay Cell signaling assay Luciferase reporter assay Cytokine releasing assay FLIPR assay Antibody internalization assay ADCC/CDC Assays were established with recombinant cell lines or endogenous cell lines and were successfully used in hybridoma screening and antibody characterization PEG or electrofusion as desired Guaranteed success for positive hybridoma High throughput cell based screening assay Functional assay for early stage screening Master or working cell banking In vitro production and affinity purification Production scale of mgs – grams Purity >95% and endotoxin at 1EU/mg or lower Featured Services Antigen and Immunogen Well-Established Screening Assays Binding assays Functional assay Animal Immunization Hybridoma Development mAb Production
Transcript of Hybridoma Development and Monoclonal Antibody Generation · Hybridoma Development and Monoclonal...
Hybridoma Development and Monoclonal Antibody Generation
ChemPartner provides premium monoclonal antibody services based on our advanced hybridoma platform which is validated by over 30 therapeutic projects and a large number of reagent mAb projects. A number of key technologies including biofunctional protein production, over-expressing stable cell line generation, tolerance breaking technologies, success guaranteed hybridoma generation, high throughput cell based screening and media compatible bioassay development and protein analytics are integrated into this platform to ensure the success of mAb development for therapeutic candidates and broad range of assay applications.
To date, we have worked with over 50 biotech and pharmaceutical companies and research institutes worldwide and delivered antibodies meeting the desired specifications and successfully in their assays and product development. We are continuously improving our service platforms and expanding our capabilities in the demanding areas such as GPCR/ion-channel antibody and ADC antibody discovery.
998 Halei Road #5 Zhangjiang Hi-Tech Park PudongShanghai, China 201203China: +86 21 5132 0000 USA: +1 781 996 5291Europe: +45 4586 9000 Japan: +81 3 [email protected] www.chempartner.com
Recombinant protein productionStable cell line generationPeptide/compound synthesis and protein conjugationPlasmid DNA construction and bullet preparation
Low-medium throughput
High throughput
Low throughput
Flow cytometry (FACS)
Acumen microplate cytometry
Immunocytochemistry (ICC/IHC)
SPF grade and multiple species/strainCPSJ mice with superior immune responseTransgenic mice for fully human antibody generationGenetic immunization
Proliferation assay Apoptosis assay Migration assay Soft agar colony formation assay Cell signaling assayLuciferase reporter assay Cytokine releasing assay FLIPR assay Antibody internalization assayADCC/CDC
Assays were established with recombinant cell lines or endogenous cell lines and were successfully used in hybridoma screening and antibody characterization
PEG or electrofusion as desiredGuaranteed success for positive hybridomaHigh throughput cell based screening assayFunctional assay for early stage screening
Master or working cell bankingIn vitro production and affinity purificationProduction scale of mgs – grams Purity >95% and endotoxin at 1EU/mg or lower
Featured ServicesAntigen and Immunogen Well-Established Screening Assays
Binding assays
Functional assayAnimal Immunization
Hybridoma Development
mAb Production
Project Timeline
SPF animals and multiple species/strains Specialzed animal strains with superior immune response to conservative antigensProprietary genetic immunization proceduresImmune tolerance breaking technology available
Fully human antibody generation from Transgenic mice Integrated services for therapeutic antibody discoveryGuaranteed success in reagent antibody generation- Anti-idiotype antibody- IHC,FACS,ELISA,WB,etc
High throghput cell based screening with Acumen microplate cytometerWell-established bioassays for hybridoma screening and mab characterizationAffinity assessment and rankBiophysical analysis available
Deliverables
All phase of screening dataSelected hybridoma cell linePurified antibody with COAAntibody characterizationdata packageLead antibody panel
Relevant Services
ADC developmentPK/PD/TK StudyIn vivo efficacy Study
